Loading
A phase 1/2 trial of Venetoclax and Azacitidine in myelodysplastic syndromes / neoplasms and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Aptose Biosciences Inc., now recruiting.
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT03850574 by Aptose Biosciences Inc., with 240 participants planned, started 2019-03-11 and due to reach its primary completion in 2026-11. Interventions recorded: Tuspetinib, Venetoclax Oral Tablet and Azacitidine for Intravenous Infusion.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Venetoclax and the tag pipeline.
Shares Azacitidine, Venetoclax and the tag pipeline.